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Background:  The second generation everolimus-eluting stent (EES) has thin stent struts and a durable biocompatible fluoropolymer that may 
reduce late stent related events compared to first generation drug-eluting stents (DES), but only limited data are available comparing late events of 
these two generations of DES.
Methods:  The SPIRIT III trial enrolled 1,002 patients with de novo lesions ≤28 mm in length and reference vessel diameter of 2.5−3.75 mm. 
Patients were prospectively randomized 2:1, XIENCE V® EES vs. TAXUS® Express2 PES. Landmark analyses of clinical outcomes, prior to and after one 
year through three years of the study follow-up, were performed on the SPIRIT III data.
Results:  At three years, cumulative rates of stent thrombosis, and myocardial infarction (MI), but not death, were numerically lower for EES 
compared to PES. Landmark analyses demonstrated that the rates of MI and stent thrombosis tended to be lower in years 1-3 for EES compared to 
PES (p=0.09 and p=0.07, respectively) (see Kaplan-Meier landmark analysis curves).
Conclusions:  Patients treated with EES tended to have fewer stent thromboses and MI during one to three years of follow-up than patients 
treated with the PES. These observations are consistent with an improved safety profile of the second generation DES, EES.
